For Immediate Release: June 07, 2021 Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over […]
Mild cognitive impairment (MCI) Overview Mild cognitive impairment (MCI) is the stage between the expected cognitive decline of normal aging and the more serious decline of dementia. It’s characterized by problems with memory, language, thinking or judgment. If you have mild cognitive impairment, you may be aware that your memory or mental function has “slipped.” […]
